Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.45 |
| ▸ | REN | P00797 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 4/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4276965 | 1.00 | CA1 (0.51) | CA1CA2CA4CA9SLC6A4 | |
| SCHEMBL4276997 | 0.86 | REN (0.51) | CA1CA2CA4CA9SLC6A4 | |
| SCHEMBL4276991 | 0.86 | REN (0.51) | CA1CA2CA4CA9SLC6A4 | |
| SCHEMBL4281201 | 0.85 | CA1 (0.58) | CA1CA2CA4CA9SLC6A4 | |
| SCHEMBL4281205 | 0.85 | CA1 (0.58) | CA1CA2CA4CA9SLC6A4 | |
| SCHEMBL4286240 | 0.83 | CA1 (0.44) | CA1CA2CA4CA9SLC6A4 | |
| SCHEMBL4286247 | 0.83 | CA1 (0.44) | CA1CA2CA4CA9SLC6A4 | |
| SCHEMBL4277247 | 0.78 | CA1 (0.53) | CA1CA2CA4CA9SLC6A4 | |
| SCHEMBL4277249 | 0.78 | CA1 (0.53) | CA1CA2CA4CA9SLC6A4 | |
| SCHEMBL3491819 | 0.78 | CA1 (0.53) | CA1CA2CA4CA9SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105251-A1 | Renin inhibitors | TAKEDA SAN DIEGO, INC. | 2009-04-23 | — | — | US | claimed |
| US-20090105251-A1 | Renin inhibitors | TAKEDA SAN DIEGO, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105251-A1 | Renin inhibitors | TAKEDA SAN DIEGO, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105251-A1 | Renin inhibitors | TAKEDA SAN DIEGO, INC. | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105251-A1 | Renin inhibitors | REN, ACE, AGT | CA1 1185/4885CA2 275/4885CA4 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.